Patents by Inventor Frances Yen-Potin
Frances Yen-Potin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110165166Abstract: The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines.Type: ApplicationFiled: February 3, 2011Publication date: July 7, 2011Applicants: Serono Genetics Institute S.A., Institut National De La Sante Et De La Recherche Medicale (INSERM)Inventors: BERNARD BIHAIN, Lydie Bougueleret, Frances Yen-Potin
-
Patent number: 7919091Abstract: The present invention relates to antibodies specific for a receptor termed the Lipolysis Stimulated Receptor (LSR). Compositions comprising the antibodies are also provided.Type: GrantFiled: September 27, 2007Date of Patent: April 5, 2011Assignees: Serono Genetics Institute S.A., Institut National de la Sante Et de la Recherche Medicale (Inserm)Inventors: Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin
-
Patent number: 7671024Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. The application is related to OBG3 polypepide fragments and compositions comprising these fragments. It also discloses methods of reducing free fatty acid levels with the polypeptide fragments of the invention.Type: GrantFiled: May 23, 2008Date of Patent: March 2, 2010Assignee: Serono Genetics Institute S.A.Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen-Potin, Bernard Bihain
-
Publication number: 20090291091Abstract: It is the object of the present invention to provide novel means for the treatment and/or prevention of thrombosis, tumor implantation, tumor seeding and metastasis. More specifically, the present invention relates to the use of a polypeptide comprising the globular head of Acrp30 for the manufacture of a medicament for treatment and/or prevention of thrombosis-related disorder, an hypertensive disorder of the pregnancy, tumor implantation, tumor seeding and metastasis.Type: ApplicationFiled: June 20, 2006Publication date: November 26, 2009Applicant: Laboratoires Serono SAInventors: Bernard Bihain, Michel Dreano, Jennifer Hantson, Virginie Ogier, Pierre-Alan Vitte, Frances Yen-Potin
-
Publication number: 20090263847Abstract: The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines.Type: ApplicationFiled: September 27, 2007Publication date: October 22, 2009Applicants: Serono Genetics Institute S.A., Institut National de la Sante et de la Recherche Medicale (Inserm)Inventors: BERNARD BIHAIN, Lydie Bougueleret, Frances Yen-Potin
-
Publication number: 20090099076Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidermias, atherosclerosis, diabetes, and hypertension.Type: ApplicationFiled: May 23, 2008Publication date: April 16, 2009Applicant: Serono Genetics Institute S.A.Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen-Potin, Bernard Bihain
-
Publication number: 20080249009Abstract: Methods and pharmaceutical compositions useful for treating obesity-related disorders using ApM-1 and related proteins.Type: ApplicationFiled: April 30, 2007Publication date: October 9, 2008Applicant: Serono Genetics Institute S.A.Inventors: Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin
-
Patent number: 7393661Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. This application pertains to nucleic acids encoding a compound, globular OBG3 polypeptide fragments, vectors and transformed host cells containing these nucleic acids and methods of making the globular OBG3 polypeptide fragments.Type: GrantFiled: May 19, 2005Date of Patent: July 1, 2008Assignee: Serono Genetics Institute S.A.Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen-Potin, Bernard Bihain
-
Patent number: 7338787Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: GrantFiled: October 20, 2004Date of Patent: March 4, 2008Assignee: Serono Genetics Institute S.A.Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen-Potin, Bernard Bihain
-
Publication number: 20070275891Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: ApplicationFiled: May 19, 2005Publication date: November 29, 2007Applicant: Genset S.A.Inventors: Joachim Fruebis, Mary Erickson, Frances Yen-Potin, Bernard Bihain
-
Patent number: 7291709Abstract: The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines.Type: GrantFiled: August 27, 2003Date of Patent: November 6, 2007Assignees: Serono Genetics Institute S.A., Institut National de la Sante de la Recherche Medicale (INSERM)Inventors: Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin
-
Patent number: 7223727Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GSSP4 polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing cholesterol levels, body mass, body fat, and for treating metabolic-related diseases and disorders. The metabolic-related diseases or disorders include, but are not limited to, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, diabetes, glucose intolerance, insulin resistance and hypertension.Type: GrantFiled: February 7, 2002Date of Patent: May 29, 2007Assignee: Serono Genetics Institute S.A.Inventors: Barbara Chicca, John Chicca, Blake Denison, Frances Yen-Potin, Bernard Bihain, Stephane Bejanin, Hiroaki Tanaka, Severin Jobert, Jean-Yves Giordano, Jean-Baptiste Dumas Milne Edwards
-
Patent number: 7220722Abstract: Methods and pharmaceutical compositions useful for treating obesity-related disorders using ApM-1 and related proteins.Type: GrantFiled: February 5, 2002Date of Patent: May 22, 2007Assignee: Serono Genetics Institute S.A.Inventors: Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin
-
Patent number: 7122644Abstract: The invention provides the genomic sequence of GSSP-2, GSSP-2 cDNAs and GSSP-2 polypeptides. Further the invention provides polynucleotides including biallelic markers derived from the GSSP-2 gene and from genomic regions flanking the gene. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid molecule containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. The invention also concerns methods and compositions for killing neoplastic cells or inhibiting neoplastic cell growth. In particular, the present invention concerns cell proliferation arresting/inhibiting and apoptosis/necrosis inducing compositions and methods for the treatment of tumors. The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides.Type: GrantFiled: April 10, 2002Date of Patent: October 17, 2006Assignee: Serono Genetics Institute S.A.Inventors: Frances Yen-Potin, Blake Denison, Aymeric Duclert, Lydie Bougueleret, Catherine Clusel, Jean-Baptiste Dumas Milne Edwards, Bernard Bihain, Barbara Bour, Dana Ebbets-Reed, Luisa Salter-Cid
-
Publication number: 20060166259Abstract: The invention provides novel APM1 genomic sequences, polypeptides, antibodies, and polynucleotides including biallelic markers derived from the APM1 locus. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Additionally, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. Further, the invention provides diagnostic methods for early detection of obesity-related disorders.Type: ApplicationFiled: March 28, 2006Publication date: July 27, 2006Applicant: Serono Genetics Institute S.A.Inventors: Lydie Bougueleret, Bernard Bihain, Blake Denison, Frances Yen-Potin
-
Patent number: 6989367Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: GrantFiled: November 1, 2002Date of Patent: January 24, 2006Assignee: Genset S.A.Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen-Potin, Bernard Bihain
-
Patent number: 6946444Abstract: Methods and pharmaceutical compositions useful for modulating lipoprotein levels in vivo. The invention stems from the discovery that activity of the Lipolysis Stimulated Receptor (LSR) can be inhibited or enhanced by exogenous agents, including polypeptides.Type: GrantFiled: January 29, 2002Date of Patent: September 20, 2005Assignee: GensetInventors: Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin
-
Publication number: 20050075285Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GSSP4 polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing cholesterol levels, body mass, body fat, and for treating metabolic-related diseases and disorders. The metabolic-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to: obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, diabetes, glucose intolerance, insulin resistance and hypertension.Type: ApplicationFiled: February 7, 2002Publication date: April 7, 2005Inventors: Barbara Bour, John Chicca, Blake Denison, Frances Yen-Potin, Bernard Bihain, Stephane Bejanin, Hiroaki Tanaka, Severin Jobert, Jean-Yves Giordano, Jean-Baptiste Dumas Milne Edwards
-
Publication number: 20050059631Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: ApplicationFiled: October 20, 2004Publication date: March 17, 2005Applicant: Genset S.A.Inventors: Joachim Fruebis, Mary Erickson, Frances Yen-Potin, Bernard Bihain
-
Publication number: 20040235709Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GSSP3 polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: ApplicationFiled: March 8, 2004Publication date: November 25, 2004Inventors: Luisa Salter-Cid, Dana Ebbets-Reed, Barbara A. Chicca, John Chicca, Frances Yen-Potin, Bernard Bihain